Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma

BACKGROUND: Previous studies have explored cancer immunotherapy with radiotherapy or anti-angiogenic therapy, but no trials have reported a triple therapy approach. This study aimed to investigate safety and clinical outcome of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Liting, Wu, Dehua, Peng, Weiwei, Sheng, Hailong, Xiao, Yazhi, Zhang, Xuebing, Wang, Yuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170410/
https://www.ncbi.nlm.nih.gov/pubmed/34094988
http://dx.doi.org/10.3389/fonc.2021.686621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170410/
https://www.ncbi.nlm.nih.gov/pubmed/34094988
http://dx.doi.org/10.3389/fonc.2021.686621

Ejemplares similares